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Abstract 
INTRODUCTION 
Psoriatic arthritis (PsA) is a chronic inflammatory disease involving peripheral 
arthritis, enthesitis, dactylitis, spondylitis, psoriasis and nail disease (1). It has a profound 
impact on patients’ physical, psychological and social well-being. The inflammation of axial 
and peripheral joints as well as entheses causes pain and possibly joint erosion and 
destruction (2). Both the acute inflammation and joint damage from PsA causes loss of 
physical function and disability (3). Physical function is a key concern from numerous 
qualitative studies among PsA patients (4, 5), and it is recognized as one of the core domains 
to be measured in every randomized controlled trial (RCTs) and longitudinal observational 
study (6). 
There have been several instruments in the form of patient-reported outcome 
measures (PROMs) that assess physical function in PsA (7). The most commonly used 
PROMs for the physical function domain (PF-PROM) in RCTs for PsA have been the Health 
Assessment Questionnaire Disability Index (HAQ-DI) (8) and the physical functioning 
domain within the Medical Outcomes Study 36-item Short Form Survey (SF-36 PF) (9). A 
few additional ones have also been validated and evaluated for use in PsA (10). The 
discriminative performance of these PF-PROMs in RCTs have not been evaluated 
systematically. In this systematic review, we aimed to evaluate the clinical trial 
discrimination properties of PF-PROMs in RCTs of PsA. The data derived from this study 
contribute to the concerted effort of the Group for Research And Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA) – Outcome Measures in Rheumatology (OMERACT) initiative 
to standardize an outcome measurement set for PsA (11). 
 
METHODS 
The protocol of this systematic review was registered with PROSPERO prior to 
initiation (CRD42019129557). The report of this systematic review adheres to the Preferred 
Reporting Items for Systematic reviews and Meta-Analysis (PRISMA statement) (12). 
Literature search and eligibility of articles 
We performed a database search through 21 March 2019 using PubMed and Scopus. 
The search aimed to identify all original full text articles of RCTs conducted in PsA with 
published data in the English language. The detail of search terms is summarized in 
supplementary table 1. We included articles on RCTs conducted in PsA only. If the RCT was 
conducted in a mixed arthritis population, we only included those with separate subgroup 
analyses in PsA. We excluded RCTs that were not double blinded in study design. 
For the purpose of deriving responsiveness data for the PF-PROMs, we limited the 
review to RCTs involving biological (b) disease modifying anti-rheumatic drugs (DMARDs) 
and targeted synthetic (ts)-DMARDs. For RCTs with multiple publications, only one article 
from each unique RCT was included unless a publication provided new information, such as 
subgroup analyses. Trials that did not report data for PF-PROMs were excluded.  
Selection of articles 
One researcher (YYL) removed duplicates from the searches of two databases. Two 
researchers (YYL, RH) independently screened the titles, abstracts and full text (if 
appropriate) for eligibility.  Disputes were resolved by consensus of the two researchers and a 
third researcher if needed. Additional studies identified by co-authors were considered for 
inclusion. The stepwise eligibility and inclusion of articles are summarized in a flow diagram 
(Figure 1). 
Extraction of study characteristics and description of PROMs 
YYL and AO independently extracted data on the characteristics of the studies 
including gender, duration of illness of participants, proportion of participants taking 
methotrexate and resistant to tumor necrosis factor inhibitors (TNFi), active interventions, 
comparisons, primary outcomes and their time points. Researchers worked in groups of two 
(YYL and RH; YYL and ASM; YYL and NG; YYL and CL) to extract data independently 
for PF-PROMs at baseline and the time point of assessment of primary outcomes (or end of 
blinded controlled periods). These assessment time points were chosen with the consideration 
that they represented responsiveness of the PF-PROM in the control groups, as most RCTs 
offered cross-over to the active intervention after the primary end point. One researcher 
(YYL) calculated the effect sizes (ESs) for the PF-PROMs based on published data and 
online supplementary materials if available. Effect sizes of PF-PROMs comparing active and 
control groups were evaluated using the following methods wherever data were available (3): 
1) ES1, calculated by change scores divided by standard deviations (SDs) of baseline scores; 
2) ES2, calculated by change scores divided by pooled SDs; and 3) standardized response 
means (SRMs), calculated by change scores divided by SDs of the change scores. 
For papers that provided standard error (SE), SD was calculated using the formula: 
SD = SE x sample size (13). For papers that included information on median and 
interquartile ranges, means (SD) were calculated using an estimation formula suggested by 
Wan et al (14). 
Quality Assessment 
We assessed the clinical trial discrimination of PF-PROMs in each article using the 
OMERACT good method checklist (15). Two researchers in groups (YYL and RH; YYL and 
ASM; YYL and NG; YYL and CL) appraised each instrument for the following categories 
using (+) yes, good methods; (+/-) some cautions; or (-) no, not achieved:  
1. Was the time interval between testing stated and appropriate? 
2. Were there proportions of people expected to change in one or both groups? 
3. Were hypotheses described regarding the anticipated mean differences in change 
scores between subgroups a priori? 
4. Were the statistical methods adequate for the hypotheses tested? 
5. Otherwise good methods? (free of any other important flaws) 
The two-researcher groups independently assessed a final decision for each article 
rated as 1) Green, likely low risk of bias; 2) Amber, some cautions but can be used as 
evidence and 3) Red, not to be used as evidence. Consensus between the two researchers 
in the group was sought and disputes were resolved with a third member of the team if 
necessary.  
Appraisal of effect sizes using a priori hypotheses and evidence synthesis 
The calculated ESs were appraised with the following a priori hypotheses (based on general 
knowledge of the therapeutic efficacy of various treatments): 
1. At the assessment time point (primary outcome or end of blinded controlled period), 
patients treated with b-DMARDs have significant changes in PF-PROM, whereas 
patients receiving the control intervention do not (except for alefacept [ALC] and 
clazakizumab ts-dn[CLZ] where no significant differences were expected). 
2. PF-PROM change scores  among patients given b-DMARDs are significantly better 
than those receiving control. PCB. 
3. Within individual trials, the  PF-PROM ESs are higher for those treated with b-
DMARDs compared with PCB, MTX or conventional synthetic (cs)-DMARD, but do 
not differ significantly with different b-DMARD doses (or with TNFi as active 
comparators). 
4. If data for subgroup analyses are available, ESs of change scores of the PF-PROM are 
higher in TNF naïve versus TNF exposed subgroups. 
We synthesized and summarized the overall evidence to support clinical trial 
discrimination for each PF-PROM in a Summary of Measurement Properties evidence table 
(SOMP). The number of articles available for measurement properties and evidence synthesis 
are presented. For each article, colour coding of  Green/Amber/Red indicated the quality 
assessment and (+), (+/-) or (-) indicated fulfilment, partial fulfilment or not supportive of the 
hypotheses. Synthesizing evidence from all articles evaluated, an overall rating for clinical 
trial discrimination of the PF-PROM was given as Green (Good to go) /Amber (Some 
concerns but good to go) /Red (Stop, do not use this for evidence synthesis), or White for no 
information available. 
RESULTS 
Literature search results 
Our literature search identified a total of 676 articles. After removal of duplicates, 608 
articles remained;. one article was identified through cross referencing check. There were 439 
articles excluded for the following reasons: not RCTs (344 articles), open-label trials (10 
articles), not in PsA (65 articles), mixed population of arthritis without separate data 
reporting for PsA (18 articles) and trial protocols (2 articles). There were 170 articles eligible 
for full text review as RCTs in PsA. We excluded 48 articles as trials for interventions other 
than b-DMARDs or ts-DMARDs, 67 as secondary analyses of RCTs in PsA, 13 without 
inclusion of PF-PROM and 9 as pooled data from RCTs. A total of 41 articles were included 
in the full text review that reported primary data on double-blind RCTs in PsA with b-
DMARDs and ts-DMARDs. In total, 33 relevant articles representing 32 RCTs were retained 
for evidence synthesis and 31 RCTs (75.6%) included data for the physical function domain 
(Figure 1).   
Of the 13 articles reporting 10 RCTs that did include physical function data, one and 
three were Phase 1b and 2 trials, respectively. Among the six Phase 3 RCTs that did not 
include physical function data,  two were pilot proof of concept studies with molecular and 
tissue focus, and three were RCTs in psoriasis, not PsA. 
In these RCTs physical function was evaluated using four PF-PROMs, including the 
Health Assessment Questionnaire (HAQ)-Disability Index (HAQ-DI) (8), HAQ-
Spondyloarthritis (HAQ-S) (16), Physical Component Summary Score of the SF-36 (SF-36 
PCS) (9), and the Physical Functioning domain of the SF-36 (SF-36 PF10) (9). New potential 
PF-PROMs shortlisted by GRAPPA for further evaluation [paper under review], including 
the multidimensional HAQ (MDHAQ) and the Patient-Reported Outcomes Measurement 
Information System (PROMIS)-Short Form Physical Function 10a (PROMIS-PF10a), were 
not utilized in the RCTs included in this review. 
Clinical trial discrimination for PF-PROM 
Results were reported for HAQ-DI in 31 articles from 30 unique RCTs . The ESs 
calculated for both interventional and comparator groups are shown in Table 2. Effect sizes 
for HAQ-DI could not be calculated from two published articles (detailed in Supplementary 
Table 6), and data were not used for evidence synthesis. Quality assessment using the 
OMERACT good method checklist was generally affirmative (Supplementary Table 2). 
Minor concerns for quality were noted in 10 articles, predominantly resulting from not clearly 
stating expected change scores in HAQ-DI (although most expected changes were implied), 
estimating ESs from median/ interquartile ranges, or using percentage changes that raised 
concerns for introduction of minor errors. There were 29 articles included for evidence 
synthesis as shown in the SOMP table (Table 6). Results aligned with the a priori hypotheses 
that statistically significant change scores were reported in the active but not control groups 
with higher ESs (Table 2). Three articles included subgroup analyses, where one 
demonstrated higher ESs for HAQ-DI in TNFi naïve compared with TNFi exposed groups 
(17), while two did not (18, 19). Based on all the evidence, the working group recommended 
GREEN (+) to support HAQ-DI in RCT discrimination in PsA, indicating a low risk of bias 
and results aligned with hypotheses. 
There was only one article that reported results for HAQ-S (20), showing higher ESs 
for the ABT-122 and adalimumab groups compared with control which aligned with the 
hypotheses (Table 3). However, no statistical test was performed for the change scores in 
different groups. The working group recommended AMBER (+) for HAQ-S (Table 6), 
recognizing that more data are required for better evidence synthesis.  
The SF-36 was included in most RCTs in PsA. However, of the 33 included articles, 
only 24 reported SF-36 PCS results and four SF-36 PF. Of the articles included for SF-36 
PCS evidence synthesis, one did not pass the OMERACT checklist for evidence synthesis. It 
failed to include adequate data for ES calculations (21); also compared with control groups, 
statistically significant differences in change scores were evident with the higher dose but not 
lower dose used in the interventional groups (Table 4). For the 23 eligible articles, most 
results aligned with the a priori hypotheses with minor quality concerns in 7 similar to those 
stated for HAQ-DI (Supplementary Table 4). The working group recommended GREEN (+) 
supporting clinical trial discrimination with SF-36 PCS. 
Four articles reported SF-36 PF, and two did not have adequate data for ES 
estimations and were excluded from evidence synthesis (Table 5). Of the remaining 2 articles, 
both with tofacitinib [ref], higher ESs in the interventional groups were shown compared with 
control (Table 5). Based on the limited evidence, the working group recommended AMBER 
(+) for clinical trial discrimination with SF-36 PF (Table 6).  
DISCUSSION 
In this systematic review, we summarized the clinical trial discrimination of the 
available PF-PROMs in PsA. Of 41 unique RCTs in PsA with b-DMARD/ ts-DMARDs, 31 
(75.6%) reported results of at least one measurement of the physical function domain. This is 
the first paper that systematically appraised the clinical trial discrimination properties for PF-
PROMs. Numerous instruments are available for assessing physical function in PsA (7, 10). 
However, data for appraisal of clinical trial discrimination was available for only four PF-
PROMs (HAQ-DI, HAQ-S, SF-36 PCS and SF-36 PF). The majority of studies reported data 
with HAQ-DI and SF-36 PCS, while only four and one reported data with SF-36 PF and 
HAQ-S, respectively. This systematic review supports clinical trial discrimination with 
HAQ-DI and SF-36 PCS with low risk of bias, whereas clinical trial discrimination with 
SF-36 PF and HAQ-S are supported with caution. There are no data published to date to 
support clinical trial discrimination for potential PF-PROMs shortlisted by GRAPPA such as 
MDHAQ and PROMIS. 
Physical function is one of the domains included in the core outcome set for reporting 
data in PsA RCTs and longitudinal observational studies  (6). GRAPPA and OMERACT are 
committed to standardizing outcome measures based on evidence but variations in reporting 
outcomes in PsA clinical trials have been recognized (11). To appropriately evaluate the 
measurement properties of instruments using the OMERACT Filter 2.1, multiple 
measurement properties are considered, including domain match, feasibility, validity, test-
retest reliability, longitudinal construct validity, clinical trial discrimination and threshold of 
meaning (15). In this study, we aimed to evaluate only the clinical trial discrimination of PF-
PROMs. Although this represents an intermediate step in standardizing the outcome 
measurement set for physical function in PsA, it is important in the process. 
The strength of the current work is the combined effort of investigators and patient 
research partners (PRPs). The investigators are familiar with the measurement of physical 
function in PsA with representation from 4 continents while the PRPs have participated in a 
wide range of research activities, including data extraction, quality assessment of articles and 
appraisal of ESs. We followed the methods recommended by the OMERACT Filter 2.1 
methodology in quality assessment of each article, calculating ESs using appropriate statistics 
to synthesize the evidence to support clinical trial discrimination (15). This was further 
strengthened by setting a priori hypotheses of the expected magnitude of ESs of 
interventional compared with control groups.  
Some limitations are recognized. We limited the evidence to RCTs with b-DMARDs 
and ts-DMARDs; and excluded RCTs evaluating solely cs-DMARDs. We think this best 
represents RCTs in the modern era that include the appropriate core domains. We calculated 
the ESs of PF-PROMs from published data instead of using the original dataset from the 
RCTs. Where applicable, we used formulas estimating means (SD) from reported medians 
(IQR), which may result in variability. Nonetheless, this variability in ES estimations has 
been recognized and addressed in the quality assessment using the OMERACT good method 
checklist; and the detailed calculations are shown in the supplementary documents. Estimated 
ESs (ES1, ES2 or SRM) were tabulated depending on availability of published data, which 
may not be directly comparable.  This would contribute only to minor differences as all 
hypothesis testing was performed intra- rather than inter- trials using the same type of ESs.  
CONCLUSION 
This systematic review supports clinical trial discrimination with HAQ-DI and SF-36 
PCS with low risk of bias, while clinical trial discrimination with SF-36 PF and HAQ-S were 
supported with some caution.  
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Figure 1. Flow diagram for article selection 
 
Table 1. Characteristics of included studies 



























Antoni, et al. 2005 
(IMPACT) (22) 
IFX 5mg/kg 
vs. PCB  
N=104 
(42.3) 
11.4 0% NA ACR20/  
Week 16 
1.2 Yes No No No 
Antoni, et al. 2005 
(IMPACT2) (23) 
IFX 5mg/kg 









1.1 Yes No - No 
Kavanaugh, et al. 
2006 (IMPACT2) 
(24) 
- - Yes - 
Mease, et al. 2005 
(ADEPT) (25) 
ADA 40mg Q2W  
vs. PCB  
N=313 
(44.4) 





Δ in modified 
total sharp 
score/ week 24 
1.0 Yes No Yes No 
Genovese, et al. 
2007 (26) 
ADA 40mg Q2W 
vs. PCB  
N=100 
(46.0) 





1.0 Yes No Yes No 
Mease, et al. 2000 
(27) 




9.3 0% 47% PsARC/  
Week 12 
1.3 Yes No No No 
Mease, et al. 2010 
(28) 




9.1 0% 41.5% ACR20/  
Week 12 
1.1 Yes No Yes No 










7.0 NA NA Psoriasis clear 
or almost 
clear/   
Week 12 
0.92 Yes No No No 
Mease, et al. 2019 
(SEAM-PsA) (30) 
ETN 50mg QW 
vs. ETN 50mg 
QW plus MTX 










1.2 Yes No Yes No 








7.5 0% 48% ACR20/ 
Week 14 
1.3 Yes No Yes No 
Kavanaugh, et al. GOL IV 2mg/kg N=480 5.8 0% 70% ACR20/ 1.3 Yes No Yes No 





























vs. PCB (48.0) Week 14 
Gladman, et al. 
2014 
(RAPID-PsA) (33) 











1.3 Yes No Yes No 
IL17 inhibitors 
McInnes, 2014 
(Phase II) (34) 
SEC (10mg/kg)  
vs. PCB (N=42) 
N=42 
(64.0) 





1.5 Yes No Yes No 
Mease, et al. 2015  
(FUTURE I) (35) 








1.2 Yes No Yes No 
McInnes, et al. 2015 
(FUTURE II) (36) 
SEC (3 doses)  
vs. PCB  
N=397 
(51.6) 





1.2 Yes No Yes No 
Kavanaugh, et al. 
2016. 
(FUTURE II) (17) 
-subgroup analysis 
TNFi naïve  
vs. TNFi exposed 
Nash, et al. 2018 
(FUTURE III) (37) 




7.5 32% 47.6% ACR20/  
Week 24 
1.2 Yes No Yes No 
Mease, et al. 2017 
(SPIRIT-P1) (38) 
IXE (2 doses)  
vs. PCB  
vs. ADA  
N=417 
(54.0) 





1.2 Yes No Yes No 
Nash, et al. 2017 
(SPIRIT-P2) (39) 
IXE (2 doses)  
vs. PCB  
N=363 
(53.4) 
10.0 100% 41% ACR20/  
Week 24* 
1.2 Yes No Yes No 
Mease, et al. 2014 
Phase II (21) 
BRO (2 doses)  
vs. PCB  
N=168 
(64.0) 
8.7 51% 50% ACR20/  
Week 12 
1.3 Yes No Yes No 
IL12/23 inhibitors 
Gottlieb, et al. 2009 
(40) 
UST (2 doses)  
vs. PCB  
N=146 
(43.8) 
5.6 27.4% 20.5% ACR20/  
Week 12 
0.9 Yes No No No 
McInnes, et al.  
2013  
(PSUMMIT I) (41) 
UST (2 doses)  
vs. PCB  
N=615 
(46.3) 




1.3 Yes No Yes No 



























Ritchlin, et al. 2014 
(PSUMMIT II) (18) 
UST  
(2 doses)  
vs. PCB  
N=312 
(52.6) 







1.0 Yes No Yes No 
Araugo, et al. 2019 
(ECLIPSA) (42) 
UST (45mg or 









1.0 Yes No Yes No 
IL23 inhibitors 






7.0 8.7% 44.3% ACR20/ 
Week24* 
1.4 Yes No Yes No 
T cell inhibition 
Mease, et al. 2011 
Phase II (44) 
ABT (3 doses)  
vs. PCB  
N=170 
(44.2) 
8.2 37.4% 58.3% ACR20/ 
Day 169 
1.2 Yes No Yes No 
Mease, et al. 2017 
(ASTRAEA) (19) 
ABT  
vs. PCB  
N=424 
(45.0) 
8.5 61% 60% ACR20/  
Week 24* 
1.3 Yes No Yes No 






5 0% 100% ACR20/ 
Week 12 
1.1 Yes No No No 
JAK inhibitors 
Mease, et al. 2017 
(OPAL Broaden) 
(46) 
TOF (2 doses)  




6.1 0% 83.9% ACR20/  
3-month 
1.1 Yes No Yes No 




TOF (2 doses)  
vs. PCB  
N=395 
(55.0) 
9.4 100% 73.6% ACR20,  
Δ in HAQ-DI/  
3-month 
1.3 Yes No No  Yes 













1.4 Yes No No Yes 
IL6 inhibitors 
Mease, et al. 2016 
Phase II (49) 




7.1 0% 69.1% ACR20/ 
Week 16 
1.4 Yes No Yes No 



























Mease, et al. 2018 







7.3 0% 100% ACR20/  
Week 12 
1.3 No Yes No No 
*early escape at Week 16.  
Abbreviations: Δ: change; ACR: American College of Rheumatology Response criteria; ABT: abatacept; ADA: adalimumab; ALC: alefacept; BIW: twice a week; BRO: 
brodalumab; CI: confidence interval; CLZ: clazakizumab; cs-DMARDs: conventional synthetic disease modifying anti-rheumatic drugs; CZP: certolizumab pegol; ETN: 
etanercept; EULAR: European League Against Rheumatism; FIL: filgotinib; GOL: golimumab; GUS: guselkumab; HAQ-DI: Health Assessment Questionnaire – Disability 
Index; IFX: infliximab; IL=interleukin; IQR: interquartile range; IV: intravenous; IXE: ixekizumab; LS: least squares; MCID: minimally clinically important difference; MTX: 
methotrexate; NA: not available; NS: not significant; PsARC: Psoriatic Arthritis Response Criteria;  PASI: Psoriasis Area and Severity Index; PCB: placebo; PCS: physical 
component summary of SF-36; PF: physical functioning domain of SF-36; QW: once a week; Q2W: once every 2-week; SD: standard deviation; SE: standard error; SEC: 
secukinumab; SF-36: Medical Outcomes Study 36-item Short Form Survey; SPARCC: Spondyloarthritis Research Consortium of Canada enthesitis index; TNFi: tumor 
necrosis factor inhibitors; TOF: tofacitinib; UST: ustekinumab; vs.: versus. 
Table 2. Effect size estimation for studies reporting HAQ-DI 
Author/ year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/  
time point 
Effect sizes at primary endpoint (unless specified) Fulfillment of a 
priori hypothesis 
Antoni, et al. 2005 
(IMPACT) (22) 
IFX 5mg/kg 




SRM¶ (for improvement) at Week 16:  
IFX = 6.07 
PCB = -0.19 
1, 2, 3 
Antoni, et al. 2005 
(IMPACT2) (23) 
IFX 5mg/kg 




SRM¶ (for improvement) at Week 14: 
IFX = 1.08 
PCB = -0.19 
1, 2, 3 
Mease, et al. 2005 
(ADEPT) (50) 
ADA 40mg Q2W  




Δ in modified Total 
Sharp Score/ 
Week 24 
SRM at Week 12: 
ADA = -0.8 
PCB = 0.2 
1, 2, 3 
Genovese, et al. 2007 (26) ADA 40mg Q2W 





SRM at Week 12: 
ADA = -0.6 
PCB = -0.33 
1, 2, 3 





ES2¥ at Week 12: 
ETN = 0.547 
PCB = 0.237 
1, 2, 3 
Mease, et al. 2010 (28) 
 






Week 24 end of double-
blind phase 
ES for Week 12: NA 
 
ES2 at Week 24 (end of double-blind phase):  
ETN = -0.597 
PCB = -0.098 
1, 2, 3 
Gniadecki, et al. 2012 
(PRESTA) (29) 
ETN 50mg BIW/QW 
vs. ETN 50mg QW/QW 
(N=752) 
Psoriasis clear or 
almost clear/   
Week 12 
ES2 at Week 12: 
ETN 50mg BIW/QW: -0.74 
ETN 50mg QW/QW: -0.69 
1, 3 
Mease, et al. 2019 
(SEAM-PsA) (30) 
ETN 50mg QW 
vs. ETN 50mg QW plus MTX 




SRM at Week 24:  
ETN = -0.733 
  ETN plus MTX = -0.685 
MTX alone = -0.646 
1, 3 
Kavanaugh, et al. 2009 
(GO-REVEAL) (31) 




SRM at Week 14:  
GOL 100mg = -0.75 
GOL 50mg = -0.62 
PCB = -0.09 
1, 2, 3 
Author/ year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/  
time point 
Effect sizes at primary endpoint (unless specified) Fulfillment of a 
priori hypothesis 
Kavanaugh, et al. 2017 
(GO-VIBRANT) (32) 





SRM at Week 14: 
GOL IV = -1.13 
PCB = -0.26 
1, 2, 3 
Gladman, et al. 2014 
(RAPID-PsA) (33) 
CZP (2 doses) 





SRM at Week 12: 
CZP 400mg Q4W = -0.83 
CZP 200mg Q2W = -0.80 
PCB = -0.44 
1, 2, 3 
McInnes, 2014 
(Phase II) (34) 
SEC (10mg/kg)  




SRM at Week 6: 
SEC = -0.680 
PCB = 0.018 
1, 2, 3 
Mease, et al. 2015  
(FUTURE I) (35) 
SEC (2 doses with loading)  




SRM at Week 24: 
SEC 150mg = -0.703 
SEC 75mg = -0.721 
PCB = 0.239 
1, 2, 3 
McInnes, et al. 2015 
FUTURE II) (36) 






SRM at Week 24: 
SEC 300mg = -1.12 
SEC 150mg = -0.96 
SEC 75mg = -0.644 
PCB = -0.522 
1, 2, 3 
Kavanaugh, et al. 2016 
(FUTURE II) (17) 
-subgroup analysis 
TNFi naïve  




SRM at Week 24  
(TNFi naïve vs. exposed): 
SEC 300mg: -1.20 vs. -1.02 
SEC 150mg: -1.15 vs. -0.71 
SEC 75mg: -0.77 vs. -0.44 
PCB: -0.63 vs -0.35 
4 
Nash, et al. 2018 
(FUTURE III) (37) 
SEC (2 doses)  




SRM at Week 24: 
SEC 300mg = -0.81 
SEC 150mg = -0.57 
PCB = -0.24 
1, 2, 3 
Mease, et al. 2017 
(SPIRIT-P1) (38) 
 
IXE (2 doses)  
vs. PCB  




SRM at Week 24: 
IXE Q2W = -0.98 
IXE Q4W = -0.85 
PCB = -0.35 
ADA = -0.74 
1, 2, 3 
Nash, et al. 2017 
(SPIRIT-P2) (39) 







SRM at Week 24: 
IXE Q2W = -0.36 
IXE Q4W = -0.55 
PCB = -0.18 
1, 2, 3 
Author/ year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/  
time point 
Effect sizes at primary endpoint (unless specified) Fulfillment of a 
priori hypothesis 
Mease, et al. 2014 
Phase II (21) 
BRO (2 doses)  




SRM¥ at Week 12: 
BRO 280mg = -0.60 
BRO 140mg = -0.38 
PCB = -0.21 
1, 2, 3 





SRM¥ at Week 12: 
UST = -0.66 
PCB = -0.14 
1, 2, 3 
McInnes, et al. 2013  
(PSUMMIT I) (41) 
UST (2 doses)  






SRM¥ at Week 24: 
UST 90mg = -0.59 
UST 45mg = -0.62 
PCB = -0.21 
1, 2, 3 
Ritchlin, et al. 2014 
(PSUMMIT II) (18) 
UST (2 doses)  






SRM¥ at Week 24: 
UST 90mg = -0.66 
UST 45mg = -0.59 
PCB = 0.00 
 
SRM¥ at Week 24:  
Subgroup analysis: TNFi naïve vs. exposed 
 UST 90mg = -0.66 vs. -0.66 
UST 45mg = -0.66 vs. -0.59 
PCB = 0 vs. 0 
1, 2, 3 
Araugo, et al. 2019 
(ECLIPSA) (42) 
UST (45mg or 100mg if body 
weight >100kg) 
vs. TNFi  
(N=47) 
Enthesitis clearance 
(SPARCC = 0)/ 
Week 24 
ES2¥ at Week 24: 
UST = 1.81 
TNFi = 1.74 
1, 2, 3 





SRM at Week 24: 
GUS = -0.82 
PCB = -0.11 
1, 2, 3 
Mease, et al. 2011 
Phase II (44) 
ABT (3 doses)  
vs. PCB  
(N=170) 
Day 169 Insufficient data for ES calculation none 
Author/ year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/  
time point 
Effect sizes at primary endpoint (unless specified) Fulfillment of a 
priori hypothesis 








SRM¥ at Week 24: 
ABT = 0.69 
PCB = 0.40 
 
SRM¥ at Week 24: 
Subgroup analysis: TNFi naïve vs. exposed 
ABT = 0.62 vs. 0.64 
PCB = 0.39 vs. 0.34 
1, 3 





% Δ in HAQ-DI: 
ALC/MTX = -24.5% 
PCB/MTX = -7.7% 
(NS) 
Inadequate data for ES calculations 
 
none 
Mease, et al. 2017  
(OPAL Broaden) (46) 
 
TOF (2 doses)  





SRM at 3 months: 
TOF 10mg = -0.78 
TOF 5mg = -0.69 
PCB = -0.36 
ADA = -0.76 
1, 2, 3 
Gladman, et al. 2017 
(OPAL Beyond) (47) 
TOF (2 doses)  
vs. PCB  
(N=395) 
ACR20,  
Δ in HAQ-DI/  
3 months 
SRM at 3 months:  
TOF 10mg = -0.64 
TOF = -0.70 
PCB = -0.26 
1, 2, 3 








SRM at Week 16: 
FIL = 1.14 
PCB = 0.56 
 
ES2 at Week 16: 
FIL = 1.04 
PCB = 0.47 
1, 2, 3 
Mease, et al. 2016 
Phase II (49) 





SRM¥ at Week 16: 
CLZ 200mg = -0.51 
CLZ 100mg = -0.77 
CLZ 50mg = -0.83 
PCB = -0.52 
1, 2, 3 
¶ SRM calculated using percentage change score and SD of percentage change;  SRM for improvement, a negative value indicate deterioration; ¥ Effect sizes estimated based 
on mean and SD of change scores calculated from median and IQR from original publication; *early escape for patients with inadequate response in the control group to 
active treatment group at Week 16; **option to switch TNFi at Week 24. 
Abbreviations: Δ: change; ACR: American College of Rheumatology Response criteria; ABT: abatacept; ADA: adalimumab; ALC: alefacept; BIW: twice a week; BRO: 
brodalumab; CI: confidence interval; CLZ: clazakizumab; CZP: certolizumab pegol; ES2: Effect size 2 (the mean difference divided by the pooled standard deviation, i.e., 
Cohen's d); ETN: etanercept; EULAR: European League Against Rheumatism; FIL: filgotinib; GOL: golimumab; GUS: guselkumab; HAQ-DI: Health Assessment 
Questionnaire – Disability Index; IFX: infliximab; IQR: interquartile range; IV: intravenous; IXE: ixekizumab; LS: least squares; MCID: minimally clinically important 
difference; MTX: methotrexate; NA: not available; NS: not significant; PsARC: Psoriatic Arthritis Response Criteria;  PASI: Psoriasis Area and Severity Index; PCB: placebo; 
PCS: physical component summary of SF-36; PF: physical functioning domain of SF-36; QW: once a week; Q2W: once every 2 weeks; SD: standard deviation; SE: standard 
error; SEC: secukinumab; SF-36: Medical Outcomes Study 36-item Short Form Survey 36 items; SPARCC: Spondyloarthritis Research Consortium of Canada enthesitis 
index; SRM: Standardized response mean (mean difference divided by the standard deviation of the differences between baseline and assessment end point); TNFi: tumor 
necrosis factor inhibitors; TOF: tofacitinib; UST: ustekinumab; vs.: versus. 
Table 3. Effect size estimation for studies reporting HAQ-S 
Author/ year/ (study 
acronyms) 
Intervention/ comparator  




PROM Effect sizes at primary end point (unless specified) Fulfillment of a 
priori hypothesis 
Mease, et al. 2018 
Phase II (20) 






HAQ-S ES1 at Week 12: 
ABT-122 240mg: -0.93 




Abbreviations: ACR: American College of Rheumatology Response criteria; ADA: adalimumab; ES1: Effect size 1 (the mean difference divided by standard deviation of 
baseline score; HAQ-S: Health Assessment Questionnaire – Spine; PCB: placebo; 
Table 4. Effect size estimation for studies reporting SF-36 PCS 
Author / year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/ 
time point 
Effect sizes at primary end point (unless 
specified) 
Fulfillment of a 
priori hypothesis 
Antoni, et al. 2005 
(IMPACT2) (23) 
IFX 5mg/kg 




SRM at Week 14: 
IFX = 0.98 
PCB = 0.13 
1, 2, 3 
Mease, et al. 2005 
(ADEPT) (50) 
ADA 40mg Q2W 




Δ in modified Total Sharp Score/ 
Week 24 
SRM at Week 12: 
ADA = 0.93 
PCB = 0.16 
1, 2, 3 
Genovese, et al. 2007 (26) ADA 40mg Q2W 





SRM at Week 12: 
ADA = 0.67 
PCB = 0.39 
1, 2, 3 
Mease, et al. 2010 (28) 
 






Week 24 end of double-blind phase 
SRM at Week 12: NA 
 
ES2 at Week 24 (end of double-blind phase): 
ETN = 0.880 
PCB = 0.073 
1, 2, 3 
Mease, et al. 2019 
(SEAM-PsA) (30) 
ETN 50mg QW 
vs. ETN 50mg QW + MTX 




SRM at Week 24: 
ETN = 0.832 
ETN plus MTX = 0.813 
MTX alone = 0.629 
1, 2, 3 
Kavanaugh, et al. 2009 
(GO-REVEAL) (31) 




SRM at Week 14: 
GOL 100mg = 0.82 
GOL 50mg = 0.74 
PCB = 0.08 
1, 2, 3 
Kavanaugh, et al. 2017 
(GO-VIBRANT) (32) 





SRM at Week 14: 
GOL IV = 1.14 
PCB = 0.46 
1, 2, 3 
Gladman, et al. 2014 
(RAPID-PsA) (33) 
CZP (2 doses) 
vs. PCB  
(N=409) 
ACR20, EULAR response/ Week 12 SRM at Week 12: 
CZP 400mg Q4W = 0.87 
CZP 200mg Q2W = 0.82 
PCB = 0.30 
1, 2, 3 
McInnes IB, 2014 
(Phase II) (34) 
SEC (10mg/kg) 




SRM at Week 6: 
SEC = 0.541 
PCB = -0.017 
1, 2, 3 
Author / year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/ 
time point 
Effect sizes at primary end point (unless 
specified) 
Fulfillment of a 
priori hypothesis 
Mease, et al. 2015  
(FUTURE I) (35) 
SEC (2 doses with loading)  




SRM at Week 24: 
SEC 150mg = 0.785 
SEC 75mg = 0.732 
PCB = 0.178 
1, 2, 3 
McInnes, et al. 2015 
FUTURE II) (36) 
SEC (3 doses) 




SRM at Week 24: 
SEC 300mg = 0.98 
SEC 150mg = 0.875 
SEC 75mg = 0.587 
PCB = 0.203 
1, 2, 3 
Kavanaugh, et al. 2016. 
(FUTURE II) (17) 
-subgroup analysis 
TNFi naïve 




SRM at Week 24: 
(TNFi naïve vs. exposed): 
SEC 300mg: 1.07 vs. 0.95 
SEC 150mg: 1.07 vs. 0.60 
SEC 75mg: 0.71 vs. 0.45 
PCB: 0.22 vs 0.27 
4 
Nash, et al. 2018 
(FUTURE III) (37) 





SRM at Week 24: 
SEC 300mg = 0.93 
SEC 150mg = 0.49 
PCB = 0.30 
1, 2, 3 
Mease, et al. 2017 
(SPIRIT-P1) (38) 






SRM at Week 24: 
IXE Q2W = 1.79 
IXE Q4W = 1.33 
PCB = 0.55 
ADA = 1.78 
1, 2, 3 
Nash, et al. 2017 
(SPIRIT-P2) (39) 







SRM at Week 24: 
IXE Q2W = 0.30 
IXE Q4W = 0.27 
PCB = 0.06 
1, 2, 3 
Mease, et al. 2014 
Phase II (21) 
BRO (2 doses) 




Difference from PCB (95% CI): 
BRO 280mg: 2.4 (0.1 to 4.6) 
BRO 140mg: 1.4 (-0.8 to 3.6) 
Insufficient data for ES calculation 
none 
McInnes, et al.  
2013  
(PSUMMIT I) (41) 
UST (2 doses) 
vs. PCB 
(N=615) 
ACR20, EULAR response,  
PASI75 
/Week 24* 
SRM¥ at Week 24: 
UST 90mg = 0.75 
UST 45mg = 0.48 
PCB = 0.24 
1, 2, 3 
Author / year/  
(study acronyms) 
Intervention/ comparator 
(sample size, N) 
Primary outcome/ 
time point 
Effect sizes at primary end point (unless 
specified) 
Fulfillment of a 
priori hypothesis 
Ritchlin, et al. 2014 
(PSUMMIT II) (18) 
UST 
(2 doses) 
vs. PCB  
(N=312) 
ACR20, EULAR response, PASI75/ 
Week 24* 
SRM¥ at Week 24: 
UST 90mg = 0.60 
UST 45mg = 0.50 
PCB = 0.30 
1, 2, 3 
Araugo, et al. 2019 
(ECLIPSA) (42) 
UST (45mg or 100mg if 
body weight >100kg) 
vs. TNFi  
(N=47) 
Enthesitis clearance  
(SPARCC = 0)/ 
Week 24 
ES2¥ at Week 24: 
UST = 2.95 
TNFi = 1.56 
1, 3 





SRM at Week 24: 
GUS = 0.88 
PCB = 0.06 
1, 2, 3 
Mease, et al. 2011 
Phase II (44) 
ABT (3 doses) 
vs. PCB 
(N=170) 
Day 169 SRM at Day 169: 
ABT 30/10 mg/kg: 0.59 
ABT 10mg/kg: 0.77 
ABT 3 mg/kg: 0.53 
PCB: 0.02 
1, 2, 3 
Mease, et al. 2017 
(ASTRAEA) (19) 
ABT 




SRM¥ at Week 24: 
ABT: 0.72 
PCB: 0.53 
1, 2, 3 
Mease, et al. 2016 
Phase II (49) 





SRM¥ at Week 16: 
CLZ 200mg = 0.52 
CLZ 100mg = 0.59 
CLZ 50mg = 0.82 
PCB = 0.57 
1, 2, 3 
¶ SRM calculated using percentage change score and SD of percentage change;  SRM for improvement, a negative value indicate deterioration; ¥ Effect sizes estimated based 
on mean and SD of change scores calculated from median and IQR from original publication; * early escape for patients with inadequate response in the PCB group to active 
treatment group at Week 16; ** option to switch TNFi at Week 24;  
Abbreviations: Δ: change; ACR: American College of Rheumatology Response criteria; ABT: abatacept; ADA: adalimumab; ALC: alefacept; BIW: twice a week; BRO: 
brodalumab; CI: confidence interval; CLZ: clazakizumab; CZP: certolizumab; ES2: Effect size 2 (the mean difference divided by the pooled standard deviation, i.e., Cohen's 
d); ETN: etanercept; EULAR: European League Against Rheumatic Diseases; FIL: filgotinib; GOL: golimumab; GUS: guselkumab; HAQ-DI: Health Assessment 
Questionnaire – Disability index; IFX: infliximab; IQR: interquartile range; IV: intravenous; IXE: ixekizumab; LS: least squares; MCID: minimally clinically important 
difference; MTX: methotrexate; NA: not available; NS: not significant; PsARC: Psoriatic Arthritis Response Criteria;  PASI: Psoriasis Area and Severity Index; PCB: 
placebo; PCS: physical component summary of SF-36; PF: physical functioning domain of SF-36; QW: once a week; Q2W: once every 2 weeks; SD: standard deviation; SE: 
standard error; SEC: secukinumab; SF-36: Medical Outcomes Study 36-item Short Form Survey; SPARCC: Spondyloarthritis Research Consortium of Canada enthesitis 
index; SRM: Standardized response mean (mean difference divided by the standard deviation of the differences between baseline and assessment end point); TNFi: tumor 
necrosis factor inhibitors; TOF: tofacitinib; UST: ustekinumab; vs.: versus. 









Effect sizes at primary 
endpoint (unless specified) 
Fulfillment 
of a priori 
hypothesis 
Antoni, et al. 2007 
(IMPACT2) (23) 
IFX 5mg/kg 




Insufficient data for effect 
size calculation 
1, 2 
Mease, et al. 2017 
(OPAL Broaden) 
 
TOF (2 doses)  





SRM at 3 months: 
TOF 10mg = 0.64 
TOF 5mg = 0.64 
PCB = 0.23 
ADA = 0.58 
1, 3 
Gladman, et al. 
2017 
(OPAL Beyond) 




Δ in HAQ-DI/ 
3 months 
SRM at 3 months: 
TOF 10mg = 0.53 
TOF = 0.64 
PCB = 0.22 
1, 3 












¶ SRM calculated using percentage change score and SD of percentage change;  SRM for improvement, a 
negative value indicate deterioration; ¥ Effect sizes estimated based on mean and SD of change scores calculated 
from median and IQR from original publication; * early escape for patients with inadequate response in the 
control group to active treatment group at Week 16; ** option to switch TNFi at Week 24;  
Abbreviations: Δ: change; ACR: American College of Rheumatology Response criteria; ABT: abatacept; ADA: 
adalimumab; ALC: alefacept; BIW: twice a week; BRO: brodalumab; CI: confidence interval; CLZ: 
clazakizumab; CZP: certolizumab pegol; ES2: Effect size 2 (the mean difference divided by the pooled standard 
deviation, i.e Cohen's d); ETN: etanercept; EULAR: European League Against Rheumatism; FIL: filgotinib; 
GOL: golimumab; GUS: guselkumab; HAQ-DI: Health Assessment Questionnaire – Disability index; IFX: 
infliximab; IQR: interquartile range; IV: intravenous; IXE: ixekizumab; LS: least squares; MCID: minimally 
clinically important difference; MTX: methotrexate; NA: not available; NS: not significant; PsARC: Psoriatic 
Arthritis Response Criteria;  PASI: Psoriasis Area and Severity Index; PCB: placebo; PCS: physical component 
summary of SF-36; PF: physical functioning domain of SF-36; QW: once a week; Q2W: once every 2 weeks; 
SD: standard deviation; SE: standard error; SEC: secukinumab; SF-36: Medical Outcomes Study 36-item Short 
Form Survey; SPARCC: Spondyloarthritis Research Consortium of Canada enthesitis index; SRM: 
Standardized response mean (mean difference divided by the standard deviation of the differences between 
baseline and assessment end point); TNFi: tumor necrosis factor inhibitors; TOF: tofacitinib; UST: ustekinumab; 
vs.: versus. 
 
Table 6. Summary of Measurement Properties Table for clinical trial discrimination 






Antoni, 2005 (IMPACT) +    
Antoni, 2005 (IMPACT2) +  +  
Kavanaugh, 2006 (IMPACT2)    + 
Mease, 2005 (ADEPT)  +  +  
Genovese, 2007 (ADA) +  +  
Mease, 2000 (ETN) +  +  
Mease, 2010 (ETN) +  +  
Gniadecki, 2012 (PRESTA) +    
Mease. 2019 (SEAM-PsA) +/-  +  
Kavanaugh, 2009 (GO-REVEAL) +  +  
Kavanaugh, 2017 (GO-VIBRANT) +  +  
Gladman, 2014 (RAPID-PsA) +  +  
McInnes, 2014 (SEC) +  +  
Mease, 2015 (FUTURE I) +  +  
McInnes, 2015 (FUTURE II) +  +  
Kavanaugh, 2016 (FUTURE II) 
-subgroup analysis 
+  +  
Nash P, 2018 (FUTURE III) +  +  
Mease, 2017 (SPIRIT-P1) +  +  
Nash, 2017 (SPIRIT-P2) +  +  
Mease, 2014 (BRO) +  +  
Gottlieb, 2009 (UST) +    
McInnes, 2013 (PSUMMIT I) +  +  
Ritchlin, 2014 (PSUMMIT II) +  +  
Araugo, 2019 (ECLIPSA) +  +  
Deodhar, 2018 (GUS) +  +  
Mease, 2011 (ABT) +/-  +  
Mease, 2017 (ASTRAEA) +  +  
Mease, 2006 (ALC) +/-    
Mease, 2017 (OPAL Broaden) +   + 
Gladman, 2017 (OPAL Beyond) +   + 
Mease, 2018 (EQUATOR) +   + 
Mease, 2016 (CLZ) +  +  
Mease, 2018 (ABT-122)  +   
Total available studies  31 1 24 4 
Total studies for evidence synthesis 29 1 23 2 
Overall rating  + + + + 
Color code in each box indicates study quality assessed by OMERACT good methods. GREEN means “yes, 
likely low risk of bias”; AMBER means “some cautions but can be used as evidence” and RED means “No, 
don’t use as evidence”. WHITE (empty boxes), indicates absence of information on that property from that 
study. (+) indicates findings of the study had adequate performance of the instrument; (+/-) indicates equivocal 
performance; (-) indicates poor performance (less than adequate). 
 
